Register to receive a free U.S. Market Report Suite for Infusion Therapy Device –MedSuite report synopsis and brochure

Baxter Canada, a leading medical products company, today reaffirmed its commitment to its Alliston, Ontario facility by investing an additional $19 million into the plant over the next two years. This announcement follows Baxter’s $7.5 million-worth of investment in 2018, with a total investment of over $26 million. The funds will be used to ensure the Alliston facility continues to be compliant with Health Canada regulatory guidelines, and will contribute to the economic well-being of the region by helping to secure existing jobs while providing indirect employment in construction and other related fields in the short to medium term.

As the only large-scale Canadian manufacturer of IV fluids and peritoneal dialysis solutions, 98% of the products manufactured in Canada are for Canadian patients and healthcare professionals. This investment will also benefit Canada by supporting a more predictable and sustainable supply of products to Canadian hospitals and patients in the future.

“The Alliston facility is truly best in class, from our management system with continuous improvement at its core, to a culture of quality and safety,” said Baxter Canada President and General Manager, Stephen Thompson. “We reviewed our North American supply chain, and this highlighted the need to invest in our Alliston plant to ensure we continue to be an integral part of our operations worldwide. We want to be able to provide support whenever required to ensure the needs of our patients and service providers are continuously met.”

Baxter Canada’s Alliston facility continues to be a critical part of Baxter’s Americas manufacturing footprint and the $26 million investment will prepare the plant for FDA registration, allowing the facility to make an impact on a global scale when needed by meeting any future potential export and growth opportunities.

“I am thrilled to see our facility recognized as a vital part of the broader Baxter network,” said Alliston Plant Manager Elaine Copsey. “To see this continued investment in our facility is a testament to the high-quality work our employees deliver each day to ensure patients and healthcare professionals are getting the life-saving products they need.”

Source: http://www.baxter.ca/en_CA/news-media/newsroom/press-releases/2018/Baxter_Canada_Invests_Over_$26_Million_In_Alliston_Facility_Producing_Life-Sustaining_Intraveneous_And_Dialysis_Solutions.page

For Further Information

More on the infusion therapy device market in the U.S. can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Infusion Therapy Devices. The full report suite on the U.S. market for infusion therapy includes infusion pumps, intravenous (IV) sets, needleless connectors (NLCs) and stopcocks.

The iData series on the market for infusion therapy devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about infusion therapy device market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Infusion Therapy Devices brochure and synopsis.